NASDAQ:MEDP Medpace (MEDP) Stock Price, News & Analysis → The Scary Fed Idea To Turn Your Dollars Into a Digital Power Grab (From Oasis Gold) (Ad) Free MEDP Stock Alerts $402.99 +7.04 (+1.78%) (As of 04:27 PM ET) Add Compare Share Share Today's Range$394.41▼$403.6050-Day Range$372.00▼$407.7752-Week Range$216.87▼$421.00Volume135,873 shsAverage Volume229,547 shsMarket Capitalization$12.48 billionP/E Ratio41.08Dividend YieldN/APrice Target$443.14 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Medpace alerts: Email Address Medpace MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside11.1% Upside$443.14 Price TargetShort InterestBearish3.66% of Float Sold ShortDividend StrengthN/ASustainability-0.62Upright™ Environmental ScoreNews Sentiment1.54Based on 5 Articles This WeekInsider TradingSelling Shares$11.82 M Sold Last QuarterProj. Earnings Growth16.30%From $11.29 to $13.13 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.88 out of 5 starsMedical Sector25th out of 913 stocksCommercial Physical Research Industry1st out of 10 stocks 3.4 Analyst's Opinion Consensus RatingMedpace has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMedpace has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Medpace's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.66% of the float of Medpace has been sold short.Short Interest Ratio / Days to CoverMedpace has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Medpace has recently increased by 3.47%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMedpace does not currently pay a dividend.Dividend GrowthMedpace does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMedpace has received a 72.85% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Medical devices engineering", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Medpace is -0.62. Previous Next 2.5 News and Social Media Coverage News SentimentMedpace has a news sentiment score of 1.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Medpace this week, compared to 7 articles on an average week.Search InterestOnly 7 people have searched for MEDP on MarketBeat in the last 30 days. This is a decrease of -30% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added Medpace to their MarketBeat watchlist in the last 30 days. This is a decrease of -89% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medpace insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,816,852.00 in company stock.Percentage Held by Insiders20.30% of the stock of Medpace is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.98% of the stock of Medpace is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Medpace's insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Medpace are expected to grow by 16.30% in the coming year, from $11.29 to $13.13 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medpace is 40.65, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 135.47.Price to Earnings Ratio vs. SectorThe P/E ratio of Medpace is 40.65, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 134.89.Price to Earnings Growth RatioMedpace has a PEG Ratio of 1.95. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioMedpace has a P/B Ratio of 21.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Medpace's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ONE stock you should be watching.Get the full story here >>> About Medpace Stock (NASDAQ:MEDP)Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.Read More MEDP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MEDP Stock News HeadlinesMay 30, 2024 | insidertrades.comMedpace Holdings, Inc. (NASDAQ:MEDP) CEO Sells $1,575,742.14 in StockMay 26, 2024 | insidertrades.comMedpace Holdings, Inc. (NASDAQ:MEDP) CEO Sells $22,000.00 in StockJune 18, 2024 | DTI (Ad)New way to “hijack” stocksWe may have just found a unique way to “hijack” the stock market… No, it’s not a matter of picking the next Amazon or guessing on the next A.I. moonshot like NVDA… Options expert, Nate Tucci, claims as long as you deploy a certain type of trade before the end of the week anyone could have a shot to target right around $1,250 in a matter of days (based on $2.5k invested) But that’s not even the best part… Unlike most methods, you don’t need to even know WHEN to exit this trade…June 9, 2024 | americanbankingnews.comMedpace (NASDAQ:MEDP) Downgraded by StockNews.comJune 4, 2024 | seekingalpha.comMedpace: Clear Winner If China Blockade SucceedsMay 29, 2024 | msn.comTD Cowen Initiates Coverage of Medpace Holdings (MEDP) with Buy RecommendationMay 29, 2024 | msn.comMizuho Initiates Coverage of Medpace Holdings (MEDP) with Buy RecommendationMay 27, 2024 | finance.yahoo.comShould You Investigate Medpace Holdings, Inc. (NASDAQ:MEDP) At US$391?June 18, 2024 | DTI (Ad)New way to “hijack” stocksWe may have just found a unique way to “hijack” the stock market… No, it’s not a matter of picking the next Amazon or guessing on the next A.I. moonshot like NVDA… Options expert, Nate Tucci, claims as long as you deploy a certain type of trade before the end of the week anyone could have a shot to target right around $1,250 in a matter of days (based on $2.5k invested) But that’s not even the best part… Unlike most methods, you don’t need to even know WHEN to exit this trade…May 14, 2024 | benzinga.comHere's How Much You Would Have Made Owning Medpace Hldgs Stock In The Last 5 YearsMay 13, 2024 | msn.comMedpace lands massive incentive deal to keep expanding in MadisonvilleMay 10, 2024 | bizjournals.comMedpace lands new incentives for expansion that's grown again to $327M in valueMay 10, 2024 | finance.yahoo.comMedpace Holdings (MEDP) Rose as it Reported Strong MatricesMay 10, 2024 | finance.yahoo.comHere's Why Medpace Holdings (NASDAQ:MEDP) Has Caught The Eye Of InvestorsMay 10, 2024 | markets.businessinsider.comJefferies Reaffirms Their Buy Rating on Medpace Holdings (MEDP)May 3, 2024 | benzinga.com$100 Invested In Medpace Hldgs 5 Years Ago Would Be Worth This Much TodayApril 30, 2024 | finance.yahoo.comMEDP- A Strong Performer that STILL Looks Attractive After Q1 ResultsApril 29, 2024 | msn.comCleveland-area company had highest stock growth in Ohio last weekApril 26, 2024 | seekingalpha.comMedpace Holdings, Inc. (MEDP) Q1 2024 Earnings Call TranscriptApril 25, 2024 | msn.comMedpace raised to Buy at Jefferies after Q1 earnings beatApril 24, 2024 | msn.comIBD Stock Of The Day Medpace Flirts With Breakout After Big Earnings ReversalApril 24, 2024 | finance.yahoo.comMedpace Holdings Inc (MEDP) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and ...April 24, 2024 | finance.yahoo.comMedpace Holdings, Inc. Just Beat EPS By 30%: Here's What Analysts Think Will Happen NextApril 24, 2024 | finance.yahoo.comMedpace Holdings, Inc. (NASDAQ:MEDP) Q1 2024 Earnings Call TranscriptApril 24, 2024 | finance.yahoo.comQ1 2024 Medpace Holdings Inc Earnings CallApril 23, 2024 | markets.businessinsider.comDecoding 5 Analyst Evaluations For Medpace HldgsApril 23, 2024 | seekingalpha.comMedpace Holdings, Inc. 2024 Q1 - Results - Earnings Call PresentationSee More Headlines Receive MEDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/22/2024Today6/18/2024Next Earnings (Estimated)7/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryN/A Current SymbolNASDAQ:MEDP CUSIPN/A CIK1668397 Webwww.medpace.com Phone(513) 579-9911Fax513-579-0444Employees5,900Year FoundedN/APrice Target and Rating Average Stock Price Target$443.14 High Stock Price Target$464.00 Low Stock Price Target$395.00 Potential Upside/Downside+10.9%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)$9.81 Trailing P/E Ratio40.72 Forward P/E Ratio35.39 P/E Growth1.95Net Income$282.81 million Net Margins15.92% Pretax Margin18.47% Return on Equity59.74% Return on Assets19.70% Debt Debt-to-Equity RatioN/A Current Ratio0.78 Quick Ratio0.78 Sales & Book Value Annual Sales$1.89 billion Price / Sales6.56 Cash Flow$10.22 per share Price / Cash Flow39.10 Book Value$18.22 per share Price / Book21.93Miscellaneous Outstanding Shares30,980,000Free Float24,693,000Market Cap$12.38 billion OptionableOptionable Beta1.39 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. August James Troendle M.D. (Age 68)Chairman & CEO Comp: $1.65MMr. Jesse J. Geiger BBA (Age 50)CPA, President Comp: $945.08kMr. Kevin M. Brady (Age 49)CFO & Treasurer Comp: $690.48kMs. Susan E. Burwig BSN (Age 61)MA, Executive Vice President of Operations Comp: $1.12MMr. Stephen P. Ewald J.D. (Age 55)Chief Compliance Officer, General Counsel & Corporate Secretary Comp: $914.64kBrandon EbkenChief Information OfficerMs. Lauren MorrisAssociate Director of Investors RelationsMr. Todd MeyersVice President of Business Development & MarketingJohn T. Wynne MBASenior Vice President of Commercial Operations & Clinical Pharmacology UnitMr. Reinilde Heyrman M.D. (Age 63)Chief Medical Officer of Medical Department More ExecutivesKey CompetitorsPRA Health SciencesNASDAQ:PRAHLaboratory Co. of AmericaNYSE:LHExelixisNASDAQ:EXELSyneos HealthNASDAQ:SYNHPrecigenNASDAQ:PGENView All CompetitorsInsiders & InstitutionsAmerican TrustBought 580 shares on 6/11/2024Ownership: 0.002%DekaBank Deutsche GirozentraleBought 1,173 shares on 6/4/2024Ownership: 0.116%August J TroendleSold 5,695 sharesTotal: $2.25 M ($395.49/share)August J TroendleSold 3,987 sharesTotal: $1.58 M ($395.22/share)Cetera Investment AdvisersBought 8,063 shares on 5/24/2024Ownership: 0.037%View All Insider TransactionsView All Institutional Transactions MEDP Stock Analysis - Frequently Asked Questions Should I buy or sell Medpace stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MEDP shares. View MEDP analyst ratings or view top-rated stocks. What is Medpace's stock price target for 2024? 7 Wall Street research analysts have issued 12-month price targets for Medpace's stock. Their MEDP share price targets range from $395.00 to $464.00. On average, they predict the company's share price to reach $443.14 in the next twelve months. This suggests a possible upside of 11.1% from the stock's current price. View analysts price targets for MEDP or view top-rated stocks among Wall Street analysts. How have MEDP shares performed in 2024? Medpace's stock was trading at $306.53 at the beginning of the year. Since then, MEDP stock has increased by 30.1% and is now trading at $398.81. View the best growth stocks for 2024 here. When is Medpace's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, July 22nd 2024. View our MEDP earnings forecast. How were Medpace's earnings last quarter? Medpace Holdings, Inc. (NASDAQ:MEDP) announced its quarterly earnings results on Monday, April, 22nd. The company reported $3.20 EPS for the quarter, topping the consensus estimate of $2.45 by $0.75. The firm earned $511 million during the quarter, compared to analyst estimates of $512.39 million. Medpace had a net margin of 15.92% and a trailing twelve-month return on equity of 59.74%. Medpace's revenue for the quarter was up 17.7% on a year-over-year basis. During the same period in the previous year, the business earned $2.27 earnings per share. What ETFs hold Medpace's stock? ETFs with the largest weight of Medpace (NASDAQ:MEDP) stock in their portfolio include Franklin Genomic Advancements ETF (HELX), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Congress SMid Growth ETF (CSMD), Argent Mid Cap ETF (AMID), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), Invesco S&P MidCap Quality ETF (XMHQ), First Trust Health Care AlphaDEX Fund (FXH) and Alpha Architect U.S. Quantitative Momentum ETF (QMOM). What guidance has Medpace issued on next quarter's earnings? Medpace issued an update on its FY 2024 earnings guidance on Monday, April, 22nd. The company provided earnings per share guidance of 10.790-11.470 for the period, compared to the consensus earnings per share estimate of 10.610. The company issued revenue guidance of $2.2 billion-$2.2 billion, compared to the consensus revenue estimate of $2.2 billion. What is August Troendle's approval rating as Medpace's CEO? 268 employees have rated Medpace Chief Executive Officer August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among the company's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Medpace own? Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Block (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG). When did Medpace IPO? Medpace (MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers. Who are Medpace's major shareholders? Medpace's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.08%), Wasatch Advisors LP (3.15%), Riverbridge Partners LLC (1.96%), TD Asset Management Inc (1.85%), Epoch Investment Partners Inc. (1.31%) and Bessemer Group Inc. (1.27%). Insiders that own company stock include Ashley M Keating, August J Troendle, August J Troendle, Kevin M Brady, Medpace Investors, Llc, Peter J O'malley, Robert O Kraft, Stephen P Ewald, Susan E Burwig, Tom C King and Wedbush Securities Inc. View institutional ownership trends. How do I buy shares of Medpace? Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MEDP) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | Sponsoredwhy 99.94% won’t make you moneyI believe there's only 5-7 stocks that you should trade in 2024. But here's the catch…because there's alway...Prosper Trading Academy | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medpace Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medpace With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
